BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11200958)

  • 1. The molecular biology of Huntington's disease.
    Ho LW; Carmichael J; Swartz J; Wyttenbach A; Rankin J; Rubinsztein DC
    Psychol Med; 2001 Jan; 31(1):3-14. PubMed ID: 11200958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances on the pathogenesis of Huntington's disease.
    Petersén A; Mani K; Brundin P
    Exp Neurol; 1999 May; 157(1):1-18. PubMed ID: 10222105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.
    Becher MW; Kotzuk JA; Sharp AH; Davies SW; Bates GP; Price DL; Ross CA
    Neurobiol Dis; 1998 Apr; 4(6):387-97. PubMed ID: 9666478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntington's disease like-2: review and update.
    Margolis RL; Rudnicki DD; Holmes SE
    Acta Neurol Taiwan; 2005 Mar; 14(1):1-8. PubMed ID: 15835282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from animal models of Huntington's disease.
    Rubinsztein DC
    Trends Genet; 2002 Apr; 18(4):202-9. PubMed ID: 11932021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioenergetics in Huntington's disease.
    Grünewald T; Beal MF
    Ann N Y Acad Sci; 1999; 893():203-13. PubMed ID: 10672239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Huntington disease. A review].
    Bonilla E
    Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Huntington's disease: clinical and molecular genetics].
    Warita H; Shiro Y; Kashihara K; Abe K
    Nihon Rinsho; 1999 Apr; 57(4):896-9. PubMed ID: 10222786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.
    Davies SW; Turmaine M; Cozens BA; DiFiglia M; Sharp AH; Ross CA; Scherzinger E; Wanker EE; Mangiarini L; Bates GP
    Cell; 1997 Aug; 90(3):537-48. PubMed ID: 9267033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
    Hannan AJ
    Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntington's disease: molecular basis of neurodegeneration.
    Rubinsztein DC; Carmichael J
    Expert Rev Mol Med; 2003 Aug; 5(20):1-21. PubMed ID: 14585171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.
    Wright DJ; Renoir T; Gray LJ; Hannan AJ
    Adv Neurobiol; 2017; 15():93-128. PubMed ID: 28674979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
    Nithianantharajah J; Hannan AJ
    Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
    Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
    Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease.
    van Dellen A; Grote HE; Hannan AJ
    Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1007-19. PubMed ID: 16445565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective neuronal degeneration in Huntington's disease.
    Cowan CM; Raymond LA
    Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in Huntington's disease.
    Gutekunst CA; Norflus F; Hersch SM
    Curr Opin Neurol; 2000 Aug; 13(4):445-50. PubMed ID: 10970063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases.
    Lunkes A; Trottier Y; Mandel JL
    Essays Biochem; 1998; 33():149-63. PubMed ID: 10488448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic mouse models of Parkinson's disease and Huntington's disease.
    Skaper SD; Giusti P
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):455-70. PubMed ID: 20522011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.